PDF herunterladen
Pharmacopsychiatry 2018; 51(01/02): e1
DOI: 10.1055/s-0037-1600991
Erratum
© Georg Thieme Verlag KG Stuttgart · New York

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

Autoren

  • C. Hiemke

    1   Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany
    2   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany

  • N. Bergemann

    3   Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy, Bad Mergentheim, Germany

  • H. W. Clement

    4   Department of Child and Adolescent Psychiatry, University of Freiburg, Freiburg, Germany

  • A. Conca

    5   Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy

  • J. Deckert

    6   Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany

  • K. Domschke

    7   Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

  • G. Eckermann

    8   Psychiatric Hospital, Kaufbeuren, Germany

  • K. Egberts

    9   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany

  • M. Gerlach

    9   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany

  • C. Greiner

    10   Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany

  • G. Gründer

    11   Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA – Translational Brain Medicine, Aachen, Germany

  • E. Haen

    12   Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany

  • U. Havemann-Reinecke

    13   Department of Psychiatry and Psychosomatics, University of Göttingen, Göttingen, Germany

  • G. Hefner

    14   Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany

  • R. Helmer

    15   Center of Epilepsy, Bielefeld, Germany

  • G. Janssen

    16   Medical Laboratory Stein, Limbach Group, Mönchengladbach, Germany

  • E. Jaquenoud

    17   Psychiatric Hospital, Königsfelden, Brugg, Aargau, Switzerland

  • G. Laux

    18   Institute of Psychological Medicine, Haag in Oberbayern, Germany

  • T. Messer

    19   Danuviuskliniken, Psychiatric Hospital, Pfaffenhofen, Germany

  • R. Mössner

    20   Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany

  • M. J. Müller

    21   Psychiatric Hospitals Oberberggruppe, Berlin, Germany

  • M. Paulzen

    11   Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, and JARA – Translational Brain Medicine, Aachen, Germany

  • B. Pfuhlmann

    22   Psychiatric Hospital Weisser Hirsch, Dresden, Germany

  • P. Riederer

    6   Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany

  • A. Saria

    23   Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria

  • B. Schoppek

    24   kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital, Munich-Haar, Germany

  • G. Schoretsanitis

    25   Department of Psychiatry, University of Bern, Bern, Switzerland

  • M. Schwarz

    26   Department of Laboratory Medicine, Ludwig Maximilian University, Munich, Germany

  • M. Silva Gracia

    12   Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany

  • B. Stegmann

    12   Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany

  • W. Steimer

    27   Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany

  • J. C. Stingl

    10   Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany

  • M. Uhr

    28   Max Planck Institute of Psychiatry, Munich, Germany

  • S. Ulrich

    29   Aristo Pharma GmbH, Berlin, Germany

  • S. Unterecker

    6   Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Würzburg, Germany

  • R. Waschgler

    30   Psychiatric Hospital, Feldkirch, Austria

  • G. Zernig

    23   Experimental Psychiatry Unit, Department of Psychiatry 1, Medical University of Innsbruck, Innsbruck, Austria
    31   Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria

  • G. Zurek

    32   Medical Laboratory Bremen, Bremen, Germany

  • P. Baumann

    33   Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. Februar 2018 (online)

Auch verfügbar auf